The estimated Net Worth of Toshinari Tamura is at least $442 Thousand dollars as of 22 August 2018. Toshinari Tamura owns over 12,000 units of FibroGen Inc stock worth over $25,480 and over the last 10 years he sold FGEN stock worth over $0. In addition, he makes $416,462 as Independent Director at FibroGen Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Toshinari Tamura FGEN stock SEC Form 4 insiders trading
Toshinari has made over 4 trades of the FibroGen Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 12,000 units of FGEN stock worth $228,600 on 22 August 2018.
The largest trade he's ever made was exercising 48,000 units of FibroGen Inc stock on 16 March 2016 worth over $126,240. On average, Toshinari trades about 11,400 units every 89 days since 2014. As of 22 August 2018 he still owns at least 63,700 units of FibroGen Inc stock.
You can see the complete history of Toshinari Tamura stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Toshinari Tamura biography
Dr. Toshinari Tamura Ph.D. serves as Independent Director of the Company. He has served on our board of directors since September 2008. He previously worked at Yamanouchi Pharmaceutical Co., Ltd., starting in 1972, and ultimately became Executive Corporate Officer and Representative Director. Following the merger to form Astellas Pharma, Inc., he was named Executive Vice President and Chief Science Officer of Astellas Pharma, Inc. and served in those roles and on the board of directors of Astellas from April 2005 until June 2008. Dr. Tamura was in charge of research and development of our PHI anemia program in 2004 and has remained familiar with the science of the program since that time. Dr. Tamura served as director of the board of KinoPharma, Inc., a drug development company, from September 2008 to March 2010. Dr. Tamura served as director of the board of IMMD Inc., a drug development company, from October 2010 to November 2012. Dr. Tamura served as an advisor to Shin Nippon Biomedical Laboratories, Ltd., a drug development company, from September 2008 to August 2015. Dr. Tamura is currently advisor to INCJ Ltd.,, a government-sponsored private equity firm (from February 2010), Japan Agency for Medical Research and Development, a government-sponsored organization to promote integrated medical R&D (from April 2015), and Japan Science and Technology Agency, a government-sponsored organization promoting science and technology (September 2012 to March 2015, and from April 2018), as well as senior advisor to PRDM Inc., a company focused on providing drug development consulting services for biotechnology companies (from February 2018). Dr. Tamura holds a Doctor of Philosophy degree and Master’s degree in Organic Chemistry from the University of Tokyo, Graduate School of Pharmaceutical Sciences. Dr. Tamura also holds a Bachelor of Science degree from Chiba University, Department of Pharmaceutical Sciences in Pharmaceutical Science.
What is the salary of Toshinari Tamura?
As the Independent Director of FibroGen Inc, the total compensation of Toshinari Tamura at FibroGen Inc is $416,462. There are 18 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of $5,856,450.
How old is Toshinari Tamura?
Toshinari Tamura is 76, he's been the Independent Director of FibroGen Inc since 2008. There are 1 older and 21 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
What's Toshinari Tamura's mailing address?
Toshinari's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Insiders trading at FibroGen Inc
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff, and Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
What does FibroGen Inc do?
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
What does FibroGen Inc's logo look like?
Complete history of Toshinari Tamura stock trades at FibroGen Inc
FibroGen Inc executives and stock owners
FibroGen Inc executives and other stock owners filed with the SEC include:
-
Kin-Hung Yu,
Chief Medical Officer -
James Schoeneck,
Chairman of the Board -
Elias Kouchakji,
Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance -
Christine Chung,
Senior Vice President, China Operations -
Pat Cotroneo,
Chief Financial Officer -
Enrique A. Conterno,
CEO & Director -
Dr. Elias Kouchakji,
Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance -
Pat Cotroneo,
Exec. Advisor to CEO -
Suzanne Blaug,
Independent Director -
Thane Wettig,
Chief Commercial Officer -
Dr. Mark Eisner M.D., M.P.H.,
Chief Medical Officer -
Thomas Kearns,
Lead Independent Director -
Jeffrey Edwards,
Independent Director -
Rory Riggs,
Independent Director -
Gerald Lema,
Independent Director -
Jeffrey Henderson,
Independent Director -
Maykin Ho,
Independent Director -
Kalevi Kurkijarvi,
Independent Director -
Toshinari Tamura,
Independent Director -
James A. Schoeneck,
Chairman -
Benjamin Cravatt,
Director -
Aoife Brennan,
Director -
Thane Wettig,
Chief Commercial Officer -
Percy Carter,
Chief Scientific Officer -
Enrique Conterno,
Chief Executive Officer, Director -
Dr. John J. Hunter Ph.D.,
Chief Scientific Officer -
Dr. Michael J. Martinelli,
Sr. VP of Technical Devel. -
Juan Graham,
Chief Financial Officer -
Dr. Barry A. Berkowitz Ph.D.,
Founder -
Jorma Routti,
Director -
K Peony Yu,
Chief Medical Officer -
Thomas B Neff,
Chief Executive Officer -
Mark Eisner,
EVP, Chief Medical Officer -
Julian N Stern,
Director -
Frank H Md Valone,
Chief Medical Officer -
Miguel Madero,
Director -
Pharma Inc. Astellas,
-
Juan Graham,
CHIEF FINANCIAL OFFICER -
Deyaa Adib,
Chief Medical Officer